This table summarises the drugs used for malaria prevention, including adult and paediatric dosages, timing and special considerations. The medications listed are atovaquone/proguanil, chloroquine, doxycycline, hydroxychloroquine, mefloquine, primaquine and tafenoquine. The guidance covers the use o...f these drugs for primary and terminal prophylaxis, as well as contraindications (e.g. G6PD deficiency, pregnancy, and psychiatric or cardiac conditions) and safety precautions for children and special populations. The aim is to help travellers and healthcare providers reduce the risk of malaria during travel.
Accessed on 27/08/2025.
more
The eEML is a comprehensive, freely accessible online database containing information on essential medicine
This document provides an overview of malaria rapid diagnostic tests (RDTs) for Principal Recipients (PRs) of Global Fund grants, indicating their eligibility for procurement under the Global Fund's Quality Assurance Policy. The included products have been assessed and approved by the WHO Prequalifi...cation of Diagnostics Programme (WHO PQ), the relevant regulatory authorities of the GHTF founding members or the Global Fund Expert Review Panel for Diagnostics (ERPD). Updates are made based on new evidence and regulatory assessments.
more
Database of the essential lists for 137 countries based on the national essential lists repository
Malaria remains a significant global health concern, with 249 million cases and 408,000 deaths reported in 2022, primarily in sub-Saharan Africa. The most vulnerable populations are children under five and pregnant women. Rapid and accurate diagnosis using microscopy or malaria rapid diagnostic test...s (mRDTs) is essential to ensure timely treatment, prevent severe disease and promote the rational use of antimalarial drugs. This UNICEF Technical Bulletin provides guidance on the procurement, quality assurance and selection of WHO-prequalified mRDTs, including considerations for areas with a high prevalence of pfhrp2/3 gene deletions. The bulletin also highlights UNICEF’s approach to sustainability, product verification and long-term arrangements with manufacturers, which ensure a reliable supply while supporting integrated child health management programmes. The bulletin serves as a valuable resource for countries, partners and programmes involved in the implementation of malaria case management and diagnostics.
more
The 2022 report reviews the global malaria diagnostics market and technological landscape to support Unitaid’s 2023–2027 strategy for quality malaria case management. The report highlights the stalled progress of malaria control efforts, the gaps in access to diagnostics and the public health im...plications of P. falciparum HRP2/3 gene deletions, which compromise the accuracy of the widely used HRP2-detecting rapid diagnostic tests (RDTs). The report analyses the malaria RDT market, noting supplier diversification, price trends and production shifts resulting from the pandemic. It also addresses the emerging point-of-care G6PD testing market, which is required to ensure the safe radical cure of P. vivax infections. It surveys technological innovation, including digital microscopy, hemozoin tests, nucleic acid detection and biosensors, while emphasising that RDTs and microscopy will remain the mainstay of case management in the near term. The report identifies market shortcomings, access barriers and opportunities to improve malaria case management and diagnostic coverage.
more
To mark the International Day of the African Child, Medicines for Malaria Venture (MMV) celebrated the inclusion of three of its antimalarial medicines on the WHO Model List of Essential Medicines (EML) and the EML for Children (EMLc). These are two artemisinin-based combination therapies (ACTs) for... adults, children and infants, and a rectal artesunate formulation for the pre-referral treatment of severe malaria in young children. The approved therapies — pyronaridine–artesunate, dihydroartemisinin–piperaquine and rectal artesunate — offer child-friendly formulations and are the first-line treatment for uncomplicated malaria caused by Plasmodium falciparum and P. vivax. Inclusion in the EMLc facilitates national adoption, improves access to high-quality treatments and addresses the disproportionate malaria burden among children under five. This supports global efforts to reduce malaria mortality and advance elimination.
more
Antimalarial chemotherapy is crucial for reducing morbidity, mortality, and drug resistance, and is the cornerstone of malaria control. Existing antimalarial drugs act at different stages of the parasite’s life cycle. These drugs range from classic agents such as chloroquine and quinine to newer a...rtemisinin derivatives. They include tissue schizonticides, blood schizonticides, gametocytocides, and sporontocides. Artemisinin and its derivatives are the most effective and fastest-acting treatment against drug-resistant Plasmodium falciparum, achieving rapid parasite clearance and reducing transmission potential. Other key drugs include mefloquine, halofantrine, proguanil, sulfadoxine–pyrimethamine, atovaquone–proguanil, tetracyclines, clindamycin and azithromycin. Each of these drugs has a specific mechanism of action, pharmacokinetics, efficacy, safety profile and contraindications. Rational drug combinations and adherence to national treatment guidelines are essential for managing resistance, ensuring safety in vulnerable populations such as children and pregnant women, and optimising therapeutic outcomes in cases of both uncomplicated and severe malaria.
more
Combination therapy is a cornerstone of modern malaria treatment, particularly in the context of widespread multidrug resistance. Using two or more antimalarial drugs with different mechanisms simultaneously enhances efficacy, shortens treatment duration, improves compliance and delays the developme...nt of resistance. Artemisinin-based combination therapies (ACTs), such as artemether–lumefantrine, artesunate–amodiaquine and artesunate–sulfadoxine/pyrimethamine, are highly effective in rapidly clearing parasites and reducing gametocyte carriage. They are also generally well tolerated. Non-artemisinin combinations, quinine-based regimens and novel combinations (e.g. piperaquine–dihydroartemisinin) offer alternative therapeutic options, although clinical experience with these remains limited. Although ACTs are the preferred first-line treatment, factors such as cost, local drug resistance patterns, safety during pregnancy and paediatric use must inform implementation and policy decisions.
more